CD47: the next checkpoint target for cancer immunotherapy

Critical Reviews in Oncology/hematology
Ridong FengChongyang Shen

Abstract

Cancer immunotherapy using checkpoint blockade has brought about a paradigm shift in the treatment of advanced-stage cancers. Unfortunately, not all patients benefit from these therapies, paving the way for other immune checkpoints to be targeted. CD47, a 'marker-of-self' protein that is overexpressed broadly across tumor types, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy. Recently, CD47 blockade by Hu5F9-G4 has shown promise combined with Rituximab in non-Hodgkin's lymphoma. Here we review the complex structure and various physiological functions of CD47 and their implications in cancer biology. Further, this review considers future directions and challenges in advancing this promising target platform to widespread therapeutic use.

Citations

Dec 29, 2020·Frontiers in Immunology·Nicolas BoucheritDaniel Olive
Mar 21, 2021·Journal of Hematology & Oncology·Julian A Marin-AcevedoYanyan Lou
Jul 2, 2021·Journal of Immunology Research·Mario Orozco-MoralesOscar Arrieta
Nov 11, 2021·ACS Biomaterials Science & Engineering·Yingying ZhangHanjie Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.